June 17, 2021

Satsuma Pharmaceuticals, Inc. Announces Positive PK, Tolerability, and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths

March 02, 2021

Satsuma Pharmaceuticals, Inc. Announces Updated STS101 Development Plan

September 11, 2020

Satsuma Pharmaceuticals, Inc. Announces Topline Results from EMERGETM Phase 3 Trial of STS101 for the Acute Treatment of Migraine

August 07, 2020

Satsuma Pharmaceuticals Announces Enrollment of First Patient in the  ASCEND™ Phase III Open-label Trial of STS101 for  Acute Treatment of Migraine

June 01, 2020

Satsuma Pharmaceuticals, Inc. Announces Completion of Enrollment for Phase 3 EMERGE Trial of STS101 for Acute Treatment of Migraine

May 19, 2020

Satsuma Pharmaceuticals, Inc. Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform

May 12, 2020

Satsuma Pharmaceuticals, Inc. Reports STS101 Development Progress in its First Quarter 2020 Financial Results

February 03, 2020

Satsuma Pharmaceuticals, Inc. Announces Publication of STS101 Phase 1 Clinical Trial Results in Headache: The Journal of Head and Face Pain

September 17, 2019

Satsuma Pharmaceuticals, Inc. Listed on NASDAQ

August 23, 2019

Satsuma Pharmaceuticals, Inc. Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

April 25, 2019

Satsuma Pharmaceuticals, Inc. Raises $62 Million in Series B Preferred Stock Financing

February 21, 2019

Satsuma Pharmaceuticals, Inc. announces advance of lead product candidate, STS101, into Phase 3 Efficacy Trial for Acute Migraine in 2019